Pembrolizumab

🧮 Dose calculator

Lung cancer (small-cell and non-small-cell) · Regimen source: FDA Keytruda · 2.2, Table 1

• • 30-min infusion. Indication and patient selection (PD-L1, MSI) per Table 1 and 2.1. No dose reductions; withhold or discontinue for immune-mediated reactions. FDA Keytruda · 2.2FDA Keytruda · 2.1FDA Keytruda · 2.3
• • Only under an oncologist; protocol, cycle interval and adjustment rest with the treating team. FDA Keytruda · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Keytruda · 8.1

  “Risk Summary Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Keytruda · 8.2

  “Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with KEYTRUDA and for 4 months after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Keytruda · 8.4

  “The safety and effectiveness of KEYTRUDA as a single agent have been established in pediatric patients with melanoma, cHL, PMBCL, MCC, MSI-H or dMMR cancer, and TMB-H cancer.”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Keytruda · 8.5

  “No overall differences in safety or effectiveness were observed between elderly patients and younger patients.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Keytruda · 8.3

  “Contraception KEYTRUDA can cause fetal harm when administered to a pregnant woman [see Warnings and Precautions (5.5) , Use in Specific Populations (8.1) ].”